Date: 2018-09-26
Type of information: Nomination
Compound: vice president
Company: Celyad (Belgium)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On September 26, 2018, Celyad announced the appointment of Carri Duncan as Vice President Corporate Development & Communications, effective as of October 1st, 2018. Carri brings broad expertise in Life Science, most recently as VP Investor Relations at Bayer. Prior to that, she worked at Egon Zehnder as a Management Consultant in the Life Science and Finance practice groups. In previous years, Carri worked as an equities analyst including on the Buy-side at Credit Suisse, where she has pioneered coverage of European Biotech equities.
- For over a decade, Carri worked as a molecular and cell biologist in academia and with Novartis and Eli Lilly in areas of developmental biology and cancer research, respectively. She earned a PhD in Neuroscience from the ETH-Zurich.
- Dr. Duncan will be based in Mont-Saint-Guibert, Belgium and will report to Dr. Christian Homsy, Chief Executive Officer.
Financial terms:
Latest news:
Is general: Yes
